Resultados: 3

J. bras. econ. saúde (Impr.); 12 (3), 2020

Objective: In the private healthcare sector in Brazil, the dearth of information regarding transfusion cost may compromise the management of conditions requiring long-term transfusion. Therefore, the present study aimed to estimate the cost of chronic red blood cell (RBC) transfusion in this context. Met...

Texto completo (link principal)     Texto completo (link alternativo)    

J. bras. econ. saúde (Impr.); 12 (3), 2020

Objective: To assess the cost-per-responder (CpR) of biologic therapies available in Brazil to treat moderate-to-severe plaque psoriasis (PsO) from the private healthcare system’s perspective. Methods: Number needed to treat (NNT) and (CpR) analyses were performed to evaluate biologic therapies’ cost...

Texto completo (link principal)     Texto completo (link alternativo)    

J. bras. econ. saúde (Impr.); 12 (2), 2020

Objective: The aim of the study was to demonstrate the economic impact of two PD-L1 immunohistochemistry (IHC) assays, SP142 versus 22C3, in the treatment with atezolizumab plus nab-paclitaxel in patients with advanced triple negative breast cancer (aTNBC) in the Brazilian private healthcare system (BPHS...

Texto completo (link principal)     Texto completo (link alternativo)